Diversity of HIV Type 1 and Drug Resistance Mutations Among Injecting Drug Users in Kenya

2013 ◽  
Vol 29 (1) ◽  
pp. 187-190 ◽  
Author(s):  
Saida Osman ◽  
Raphael W. Lihana ◽  
Rukia M. Kibaya ◽  
Azumi Ishizaki ◽  
Xiuqiong Bi ◽  
...  
Keyword(s):  
Drug Resistance ◽  
Drug Users ◽  
Injecting Drug Users ◽  
Resistance Mutations ◽  
Drug Resistance Mutations ◽  
Hiv Type 1

scholarly journals Drug Resistance Mutations and Genetic Diversity in Patients Treated for HIV Type 1 Infection in Rural Care Centers in Togo

2016 ◽  
Vol 06 (03) ◽  
pp. 111-115
Author(s):  
Anoumou Dagnra ◽  
Abla Konou ◽  
Mounerou Salou ◽  
Pascal Kodah ◽  
Damobé Kombate ◽  
...  
Keyword(s):  
Genetic Diversity ◽  
Drug Resistance ◽  
Resistance Mutations ◽  
Drug Resistance Mutations ◽  
Hiv Type 1 ◽  
Rural Care

Prevalence of HIV Type 1 Antiretroviral Drug Resistance Mutations in Vietnam: A Multicenter Study

2011 ◽  
Vol 27 (7) ◽  
pp. 797-801 ◽  
Author(s):  
Jonathan Dean ◽  
Thu Hong Ta Thi ◽  
Linda Dunford ◽  
Michael J. Carr ◽  
Linh Thuy Nguyen ◽  
...  
Keyword(s):  
Drug Resistance ◽  
Multicenter Study ◽  
Resistance Mutations ◽  
Antiretroviral Drug Resistance ◽  
Drug Resistance Mutations ◽  
Antiretroviral Drug ◽  
Hiv Type 1

scholarly journals Impact of HIV Type 1 Subtype on Drug Resistance Mutations in Nigerian Patients Failing First-Line Therapy

2011 ◽  
Vol 27 (1) ◽  
pp. 71-80 ◽  
Author(s):  
B. Chaplin ◽  
G. Eisen ◽  
J. Idoko ◽  
D. Onwujekwe ◽  
E. Idigbe ◽  
...  
Keyword(s):  
Drug Resistance ◽  
Resistance Mutations ◽  
First Line ◽  
Drug Resistance Mutations ◽  
First Line Therapy ◽  
Line Therapy ◽  
Hiv Type 1

scholarly journals Short Communication: Characterization of Drug-Resistance Mutations in HIV Type 1 Isolates from Drug-Naive and ARV-Treated Patients in Bulgaria

2008 ◽  
Vol 24 (9) ◽  
pp. 1133-1138 ◽  
Author(s):  
Maria Mercedes Santoro ◽  
Massimo Ciccozzi ◽  
Claudia Alteri ◽  
Stefania Montieri ◽  
Ivailo Alexiev ◽  
...  
Keyword(s):  
Drug Resistance ◽  
Short Communication ◽  
Resistance Mutations ◽  
Drug Resistance Mutations ◽  
Drug Naïve ◽  
Hiv Type 1

No Increase in HIV Drug Resistance Mutations among Injecting Drug Users on Methadone Maintenance Therapy: A Prospective Cohort Study

2020 ◽  
Vol 18 (5) ◽  
pp. 362-372
Author(s):  
Chunyuan Huang ◽  
Li Ye ◽  
Abu S Abdullah ◽  
Bingyu Liang ◽  
Junjun Jiang ◽  
...  
Keyword(s):  
Drug Resistance ◽  
Maintenance Therapy ◽  
Prospective Cohort ◽  
Drug Users ◽  
Methadone Maintenance ◽  
Injecting Drug Users ◽  
Methadone Maintenance Therapy ◽  
Hiv Positive ◽  
Resistance Mutations ◽  
Drug Resistance Mutations

Background: Whether HIV-positive injecting drug users (IDUs) are at higher risk of developing drug resistance mutations (DRMs) after methadone maintenance therapy (MMT) than any other HIV-positive population is unclear. Objective: To compare the incidence of new DRMs in two population groups: antiretroviraltreatment (ART) HIV-positive IDUs and non-drug users. Methods: A prospective cohort of ART HIV-positive patients including IDUs who received MMT (MMT group) and non-drug users (N-MMT group) was established from April 2016 to December 2017 in Guangxi, China. Results: Of the 80 participants, 43 were in the MMT group and 37 were in the N-MMT group. Compared with the N-MMT group, the HRs of PIs, NRTIs and NNRTIs for new DRMs in the MMT group was 1.55 (95%CI: 0.28-8.64; P = 0.616), 1.51 (95%CI: 0.44-5.20; P = 0.512) and 0.45 (95%CI: 0.15-1.35; P = 0.155), respectively. There was no dose-response relationship between MMT and new DRMs for PIs, NRTIs and NNRTIs (P > 0.05). The new DRM incidence for NRTIs (138.23 per 104 person-months) was higher than for PIs (94.16 per 104 person-months) and NNRTIs (95.41per 104 person-months) in the MMT group, while the new DRM incidence for NNRTIs (208.24 per 104 person-months) was higher than for PIs (44.13 per 104 person-months) and NRTIs (91.78 per 104 person-months) in the N-MMT group. Conclusion: Among ART HIV-positive patients, there is no significant difference in the incidence of new DRMs between IDUs receiving MMT and non-drug users. MMT has little impact on the development of DRMs among IDUs.

scholarly journals Drug Resistance Mutations in HIV Type 1 Isolates from Patients Failing Antiretroviral Therapy in Morocco

2012 ◽  
Vol 28 (8) ◽  
pp. 944-948 ◽  
Author(s):  
Hicham El Annaz ◽  
Patricia Recordon-Pinson ◽  
Rida Tagajdid ◽  
Toufik Doblali ◽  
Bouchra Belefquih ◽  
...  
Keyword(s):  
Drug Resistance ◽  
Antiretroviral Therapy ◽  
Resistance Mutations ◽  
Drug Resistance Mutations ◽  
Hiv Type 1

Sustained Profile of Transmitted Drug Resistance Mutations for More Than 10 Years in an HIV Type 1-Infected Patient

2011 ◽  
Vol 27 (1) ◽  
pp. 41-45 ◽  
Author(s):  
Lorena Martínez-Prats ◽  
Joanna Luczkowiak ◽  
Francisca Gutiérrez ◽  
Sagrario Zurita ◽  
Silvana Fiorante ◽  
...  
Keyword(s):  
Drug Resistance ◽  
Infected Patient ◽  
Transmitted Drug Resistance ◽  
Resistance Mutations ◽  
Drug Resistance Mutations ◽  
Hiv Type 1

Drug Resistance Mutations of HIV Type 1 Non-B Viruses to Integrase Inhibitors in Treatment-Naive Patients from Sub-Saharan Countries and Discordant Interpretations

2012 ◽  
Vol 28 (9) ◽  
pp. 1157-1160 ◽  
Author(s):  
Marjorie Monleau ◽  
Avelin F. Aghokeng ◽  
Benedicte A. Nkano ◽  
Marie-Laure Chaix ◽  
Martine Peeters, and the AC11/AC12 ANRS Wor
Keyword(s):  
Drug Resistance ◽  
Integrase Inhibitors ◽  
Resistance Mutations ◽  
Drug Resistance Mutations ◽  
Treatment Naïve ◽  
Hiv Type 1 ◽  
Sub Saharan
Sign in / Sign up

Export Citation Format

Share Document